Xeroderma pigmentosum
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Xeroderma pigmentosum Classification and external resources | |
| ICD-10 | Q82.1 |
|---|---|
| ICD-9 | 757.33 |
| DiseasesDB | 14198 |
| eMedicine | derm/462 neuro/399 |
| MeSH | D014983 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Xeroderma pigmentosum, or XP, is an autosomal recessive genetic disorder of DNA repair in which the body's normal ability to remove damage caused by ultraviolet (UV) light is deficient. This leads to multiple basaliomas and other skin malignancies at a young age. In severe cases, it is necessary to avoid sunlight completely.
Causes
Damage to DNA in epidermal cells occurs during exposure to UV light. The absorption of the high energy light leads to the formation of pyrimidine dimers, namely CPDs (Cyclobutane-Pyrimidine-Dimers) and 6-4PP (pyrimidine-6-4-pyrimidone photoproducts). The normal repair process is called nucleotide excision repair. The damage is excised by endonucleases, then the gap is filled by a DNA polymerase and sealed by a ligase. The most common defect in xeroderma pigmentosum is a genetic defect whereby nucleotide excision repair (NER) enzymes are mutated, leading to a reduction in or elimination of NER.
Unrepaired damage can lead to mutations, altering the information of the DNA. If mutations affect important genes, like tumour suppressor genes (e.g. p53) or proto oncogenes then this may lead to cancer. Since in XP patients the frequencies of mutations is much elevated, these patients have a predisposition for cancer.
Types
There are 7 complementation groups, plus one variant form:
| Type | Diseases Database | OMIM | Gene | Locus | Also known as/Description |
| Type A, I, XPA | 29877 | 278700 | XPA | 9q22.3 | Xeroderma pigmentosum group A. Classical form of XP. |
| Type B, II, XPB | 29878 | 133510 | XPB | 2q21 | Xeroderma pigmentosum group B. |
| Type C, III, XPC | 29879 | 278720 | XPC | 3p25 | Xeroderma pigmentosum group C. |
| Type D, IV, XPD | 29880 | 278730 278800 | XPD ERCC6 | 19q13.2-q13.3 , 10q11 | Xeroderma pigmentosum group D or De Sanctis-Cacchione syndrome. De Sanctis-Cacchione syndrome can be considered a subtype of XPD. |
| Type E, V, XPE | 29881 | 278740 | DDB2 | 11p12-p11 | Xeroderma pigmentosum group E. |
| Type F, VI, XPF | 29882 | 278760 | ERCC4 | 16p13.3-p13.13 | Xeroderma pigmentosum group F. |
| Type G, VII, XPG | 29883 | 278780 133530 | RAD2 ERCC5 | 13q33 | Xeroderma pigmentosum group G. |
| Type V, XPV | 278750 | POLH | 6p21.1-p12 | Xeroderma pigmentosum variant. XPV patients suffer from mutation in a gene that codes for a specialized DNA polymerase called polymerase-η (eta). Polymerase-η can replicate over the damage and is needed when cells enter S-phase in the presence of a DNA-damage. |
Symptoms
Some of the most common symptoms of XP are:
- An unusually severe sunburn after a short sun exposure. The sunburn may last for several weeks. The sunburn usually occurs during a child’s first sun exposure.
- Development of many freckles at an early age.
- Irregular dark spots on the skin.
- Thin skin.
- Excessive dryness of skin.
- Rough-surfaced growths (solar keratoses), and skin cancers.
- Eyes that are painfully sensitive to the sun and may easily become irritated, bloodshot, and clouded.
- Blistering or freckling on minimum sun exposure.
- Premature aging of skin, lips, eyes, mouth and tongue.
Treatment
The most important part of managing the condition is reducing exposure to the sun.
The number of keratoses can be reduced with Isotretinoin ([3]) (though there are significant side-effects.) Existing keratoses can be treated using cryotherapy or fluorouracil.[1]
See also
References
External links
- XP Society
- XP Family Support Group
- UK Patient Support Group
- An article about this disorder in English and Italian
- Web Site of a Short Film about an Xeroderma pigmentosum (XP) Patient. Film is directed by Kimberly Williams Paisley
- Article About the Xeroderma pigmentosum (XP) Society by William Lambers (pdf format)
de:Xeroderma pigmentosumfr:Xeroderma pigmentosum id:Xeroderma pigmentosum he:קסרודרמה פיגמנטוסום nl:Xeroderma pigmentosum ja:色素性乾皮症sr:Ксеродерма пигментозум
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
